Abstract
A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have